Operates as a chemical and biotechnology company

Emergex Vaccines Holding Ltd. is a biotechnology company, which engages in the development of medicines against viral and bacterial infectious diseases. It focuses on the vaccines for dengue fever, Zika, Ebola, pandemic flu, and serious intra-cellular bacterial infections. The company was founded by Storme Moore-Thornicroft and Thomas Rademacher in 2016 and is headquartered in Abingdon, the United Kingdom.

Shanghai Shape Memory Alloy Co., Ltd. engages in the research and development, production, and marketing of occluders and vascular plugs. Its business activities include development of shape memory alloys, production of embolism equipment, and export and import business. The company was founded on May 5, 1994 and is headquartered in Shanghai, China.

IMMUNOTOPE is a clinical stage biotechnology company developing immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Their products activate the patient’s own immune system to fight disease and prevent recurrence. Their comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the very earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Their product portfolio includes ovarian, breast, prostate, lung, pancreatic and colon cancer and HBV, HCV, HIV, Influenza and Dengue viral vaccines.

Gansu Okay Medical Engineering Development Co., Ltd., established on 2014-04-15, Business scope includes medical research and experimental development;Medical equipment and equipment manufacturing;Wholesale of medical supplies and equipment;Meeting,Exhibition and related services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)***

Huizhou Hydraulics Medical Co., Ltd., established on 2016-07-13, The business scope includes medical device products,R & D, production and sales of protective equipment;Computer hardware and software,Technical development and sales of scientific instruments;Import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Rhythm Medical Technology Co., Ltd., established on 2018-06-26, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Shanghai Fujinon Medical Equipment Co., Ltd., established on 2001-01-09, The scope of business includes the international trade of medical devices in the region,Re-export trade,Trade and trade agency between enterprises in the region,Commodity display and trade consulting services in the region. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Beijing Handian Pharmaceutical Co., Ltd., established on 2005-05-08, The scope of business includes the production of granules,hard capsule,tablet,Pills;Technical extension services;design,make,acting,Place an ad;Import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Red Sun Pharmaceutical Co., Ltd., established on 2003-07-31, Business scope includes wholesale of Chinese patent medicines,Chemicals,Chemical API,antibiotics,biochemical drug(The drug business license is valid until2024year05moon21day);Technical extension services;Medical Research(Does not include medical activities);design,make,acting,Place an ad;Business Management Consulting;buisness planning;Economic and Trade Consulting;Import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Part of Synairgen Plc, Synairgen Research Ltd. is a British company located in Southampton that engages in respiratory biology and develops novel therapies. It was founded in 2003.\nThe company says this about itself: Synairgen Research Limited is a respiratory drug discovery and development company. Synairgen leverages its deep understanding of respiratory biology to discover and develop novel therapies in areas of high unmet respiratory medical need, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Using our BioBank platform (consisting of human tissue models of respiratory disease), and our clinical trial capabilities, Synairgen's strategy is to identify novel drug targets, progress them through early stage clinical trials and license them to partners to advance through to ommercialisation. The BioBank platform gives us competitive advantage by being able to use tissue from patients with disease to identify targets that would not reveal themselves in other discovery systems (e.g., the mouse). We also use the technology to test new compounds against these targets. The net effect is that as we progress programmes towards and in the clinic we do so with greater confidence because we know that the programme is underpinned by human sample based science.

Shanghai East Hospital is a Chinese private company located in Shanghai. The firm operates hospital.

Peking University First Hospital is a company headquartered in Beijing, China and ultimately controlled by the Government of China. The firm operates as a hospital.

Shenzhen Santi Medical Technology Co., Ltd., established on 2019-01-04, Business scope includes general business items:Medical Research and Experimental Development;Biomedical Technology Research;Regenerative Medicine Anti-aging Research Services;Medical technology research and development;drug development;Medical technology promotion service;Medical Technology Consulting,communication service;Medical technology transfer service;Medical Equipment Repair;Medical equipment rental service;Medical supplies and equipment retail(Does not contain drugs and medical devices);Operation of non-licensed medical devices;Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Mechanical Technology Consulting,communication service;Commodity wholesale trade(Except for licensed and approved products);Commodity retail trade(Except for licensed and approved products).,The licensing program is:

Shanghai Feilei Technology Co., Ltd., established on 1999-03-29, Business scope includes medical devices,Technology development in the field of computer science,technology transfer,technical consulting,Technical Services,electronic equipment,communication equipment,photographic equipment,Electrical Equipment,Auto Parts,Computer hardware and software,stationery,Chemical raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Sales of daily necessities,Engaged in the import and export of goods and technology,Own Equipment Rental(Not to engage in financial leasing),Own house rental. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Qingdao Aoke Biological Development Co., Ltd., established on 2003-07-17, Business scope includes cord blood preservation and development research;Technology development of cell engineering related products;Development of Cell Series Technology Engineering;cell therapy technology,cell antibody,Technology development of gene medicine;Research and development of biological reagents,Sales(Does not contain drugs,medical instruments,dangerous goods);Immune Cells,umbilical cord,placenta,Adipose stem cell preservation and development research(Clinical application of stem cell transplantation technology not included);Production,wholesale,retail cosmetics;medical service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Changzhou Waston Medical Appliance Co. Ltd. is a private company headquartered in China that manufactures medical device.

Tianjin Medical University General Hospital (Chinese: 天津医科大学总医院) is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen’s business strategy is the realisation of value via licensing transactions – as demonstrated through the out-licensing of SNG001 to AstraZeneca in 2014. Synairgen is quoted on the London Stock Exchange (LSE:SNG).